Traditionally, genetic studies in cancer are focused on somatic mutations found in tumors and absent from the normal tissue. However, this approach omits inherited component of the cancer risk. We assembled exome sequences from about 2,000 patients with different types of cancers: breast cancer, colon cancer and cutaneous and ocular melanomas matched to more than 7,000 non-cancer controls. Using this dataset, we described germline variation in the known cancer genes grouped by inheritance mode or inclusion in a known cancer pathway.
INTRODUCTION
Analysis of inherited predisposition to cancer usually involves cohorts of early disease onset patients or large kindreds. Here we analyzed a large cohort of genetically enriched (early onset and/or familial) and unselected cases of breast cancer, colon cancer and cutaneous and ocular melanomas (in total about 2,000 cases matched to more than 7,000 non-cancer controls) to develop a search strategy for novel germline cancer risk genes. By first analyzing known cancer predisposition genes, we demonstrate that protein truncating, rather than missense, mutations are the main driver of inherited solid tumor cancer predisposition and generally these occur in genes tolerant of loss-of-function mutations -distinct from the highly-constrained genes more often somatically mutated and found to be drivers in tumors. Interestingly, we find that unselected cancer cases have a significant burden of protein-truncating variants in known cancer risk genes, similar to that observed in genetically enriched (familial and early-onset, herein referred to as 'selected') patients. Using these observations to design our search for new cancer genes, we analyzed individual cancer cohorts with matched controls and constructed a ranked list of new potential candidate risk genes.
RESULTS

Cohort and overview
For this study, germline DNA from selected "genetically-enriched" cases (individuals with familial cancer and/or onset of the disorder at age of 35 or earlier) of breast cancer, colon cancer, cutaneous and ocular melanomas, and Li-Fraumeni syndrome (with primary breast cancer) was collected (Inclusion criteria is included in Supplementary Methods). We also included anonymous germline DNA sequences from specific cancer types from TCGA that were used as "unselected" cancer cases (not controlling for family history or age of onset). In total 845 "genetically-enriched" cases, 1496 "unselected" cases and 7924 controls passed quality-check and were included in subsequent analysis ( Supplementary Table 1 ).
To ensure close ancestral matching, we performed principal component analysis (PCA; Sup. Fig. 1A ) of the case and control cohorts. To reduce heterogeneity due to diverse population admixture, only the single largest cluster representing predominantly European ancestry was further analyzed. Within European-ancestry samples we performed relatedness analysis and removed all duplicates and first-degree relatives (PI_HAT > 0.2). Examination of common synonymous variants (MAF>5%) revealed a null-distribution of the Fisher's exact test statistic between cases and controls (details in Methods Section) (Sup. Fig.   1B ).
Search strategy for new cancer risk genes
Discovery of over 100 germline predisposition genes in cancer have not only revolutionized identification of individuals and families at higher risk, but also provided novel mechanistic insights into the role of pathways in cancer development 1 and helped in mitigating the risk using appropriate clinical management. This is true, not only in adult cancers, but also in diverse pediatric cancers. To define an exome-wide strategy to search for new cancer predisposition genes, we began by analyzing rare genetic variation in known risk genes. Specifically, we examined the abundance of risk alleles in known genes grouped by reported mendelian models of inheritance and known tumor suppressive activity or involvement in DNA repair pathways. We identified features common to genes in each group and compared genetic association observed in selected and unselected cancer cases (Sup. . Table 3 A-D, Sup. Fig. 2A ).
We also observed enrichment in DNA repair pathway list only in selected cases, to further investigate this signal we noted, that BRCA1 and TP53 are present in both this and autosomal dominant model list. We removed these two genes from both lists and repeated analysis. Autosomal dominant genes remain highly significant and DNA repair pathway genes association signal is lost (Sup. Table 3 E-F). We further considered autosomal dominant model to be the only significantly associated. Separate analysis of protein-truncating variants (nonsense, frameshift and essential splice site) and damaging missense (Supplementary Methods) was performed. Unselected cases (p=6.41 x 10 -6 ;
OR=2.45; OR CI=1.66-3.56) show similar significant enrichment to genetically enriched cases (p=5.26x10 -10 ; OR=3.67; OR CI=2.47-5.37) with rare (minor allele count less or equal to 10) protein-truncating variants only, while we observed no enrichment in damaging missense variation (p=0.68 and p=0.37 for selected and unselected respectively) ( Fig. 1 ). It is worth noting, however, that selected cases dataset was assembled by initial genetic screening of probands that satisfy NCCN genetic testing criteria. If tested positive, they were not subsequently included in this study, and it is possible that genetically enriched cases have had more genetic screening in general and that some diagnosed cases were removed before being entered in this study sample -likely attenuating the strength of association to the group with known autosomal dominant cancer predisposition genes. We tried multiple analyses for the recessive model, including counting of samples with more than 1 heterozygous genotype in the same gene and expanding the set of included variants up to minor allele frequency less than 1%, however the counts were still very low and inconclusive, thus the recessive model was not further tested. We looked into the frequency spectrum for the variants with MAC<=10 and observed that this association signal is driven almost entirely by singletons (Sup. Fig. 2B ).
We then asked whether there were any additional features characterizing which genes within the autosomal dominant list were driving the truncating variant association signal. Using a metric of genic tolerance to truncating variation (pLI) defined by the Exome Aggregation Consortium (ExAC), we separately estimated association in genes tolerant of loss-of-function mutations (pLI<0.1) and intolerant of such variation (pLI>0.9) (Sup. Fig. 3A ). While this list contains genes that carry either heritable risk of cancer or high-risk somatic mutations (or both) we observe high enrichment of protein-truncating variants in highly tolerant genes (p=1.5 x 10 -6 selected cases and p=3 x 10 -4 unselected cases, Sup. Fig   3B, 3C) , consistent with modest selection pressure due generally post-parental age of the disease onset.
Using these identified properties of the known cancer susceptibility genes, we
can infer what features we should expect to observe in novel germline candidate genes. We therefore targeted our search for mutations (primarily truncating) with autosomal dominant model of inheritance, in genes tolerant of loss-of-function mutations (as predicted by pLI score metric) and driven by a substantial burden of singletons (or independent variants) in both genetically enriched and unselected cases.
Case-control analysis
We applied this search strategy to our complete dataset. We found 4021 and 6254 singleton protein-truncating variants in selected and unselected cases respectively. We kept only genes with pLI<0.1 for further analysis. Because of earlier demonstrated significant contribution of inherited risk in unselected cases we joined both case cohorts for further analysis. Considering the burden of singleton truncating variants, among the top 5 genes identified with our methodology, 3 are known cancer risk genes -BRCA1, BRCA2 and ATM. While this serves as a good proof-of-concept and suggests that the exome sequencing and analysis approach has some degree of both sensitivity and specificity, there are clearly no significant novel candidates discovered from this approach (Supplementary Tables 4-6) .
Individual Cohorts Analysis
We then performed analysis of the individual phenotypic cohorts for each cancer.
Additional 3526 controls were matched to the unselected cases and were used as a replication set (Sup. Fig. 4 ). In addition to our primary analysis focused on burden of protein-truncating variants, two other previously reported models for rare variant association studies (RVAS) were used for analysis 3 which added additional variants to the truncating variants: addition of the missense mutations (c-alpha, VT tests) and ultra-rare variation analysis (variants filtered for MAF<10 -5 in ExAC). Detailed analysis of the cutaneous and ocular melanomas cohorts is available in our earlier report 4 .
We performed gene-based rare variant association testing for each gene using the earlier developed composite multi-test model 4, 5 . For analysis of the breast cancer patients, we eliminated all male samples from the dataset, resulting in comparison of 354 genetically enriched cases with 2190 matched controls. Despite the screening of the previously known BRCA1 risk mutations in the breast cancer cohort we still observe genome-wide significant rare loss-offunction variants burden in this gene (Sup. Tables 7-9). Genes with p-value less than 1x10 -4 were taken into replication. MKL2 was also included in the short-list of genes as it appears second only to BRCA1 in the burden of protein-truncating variants ( Supplementary Table 8 ). According to GTEx database 6 -MKL2 is primarily expressed in adipose and mammary tissues. Two genes show evidence of replication -BRCA1 and HSD17B1. Interestingly, four genes out of our shortlist of candidates are known to be associated with worse outcome of breast cancer, once mutated or amplified in tumors -BRCA1, HSD17B1, PCDHB15 and MED28 [7] [8] [9] [10] .
Similarly, ATM appears as a top gene in RVAS of the colon cancer cohort.
Being a known predisposing gene for this phenotype it does not reach significance threshold due to statistical power limitations ( Table 2, Sup. Tables   10-12 ). Another known colorectal cancer susceptibility gene MSH2 (P=5.8x10 -4 ) was also rediscovered in these analyses (Sup. Table 11 ). Some of the top candidate genes such as OBP2A and TMEM14C do not have expression specificity to colon tissues.
Discussion
Our study develops a systematic approach for search of the novel cancer risk genes through analysis of the rare variation in the known susceptibility genes.
Moreover, we observe notable enrichment of the known inherited genetic risk factors in the unselected cancer cohort (TCGA). Despite common beliefs that sporadic cancer cases are mostly elucidated by replicative oncogenesis 11 , aging and carcinogen exposure, genetic predisposition plays substantial role in the disease onset, comparable to genetically enriched cohort. List of the genes that we used as a training model includes well-established high-risk genes.
Expectedly, we did not find potential candidate genes in our dataset with comparable effect size. At the same time, lower-risk genes require large cohorts providing enough statistical power. Individual cohort analysis provides alternative approach to the search for candidate genes. We identified three potential candidates -HSD17B1, PCDHB15, MED28 with reported association to worse outcome for patients with somatic mutations in these genes. The HSD17B1 gene produces an enzyme that catalyzes the conversion of estrone to estradiol and estrogen exposure influences risks of breast and endometrial cancer 8 Table 1 ). All samples were sequenced using the same capture reagents at the Broad Institute and aligned on the reference genome with BWA-MEM algorithm (version 0.7.12-r1039) 13 and the best-practices GATK/Picard Pipeline, followed by joint variant calling with all samples processed as a single batch using GATK v 3.1-144 Haplotype Caller [14] [15] [16] . The resulting dataset had 7,094,027 distinct variants. Haplotype Caller, which was used for the ExAC database 17 , was also used to detect indels. Selected mutations in CDKN2A, BRCA1 and BAP1 were confirmed with Sanger sequencing.
We performed principal component analysis (PCA) on common (MAF>5%) autosomal independent SNPs to filter out all non-European samples with Eigenstrat 18 . Relatedness analysis among Europeans was conducted with PLINK 19, 20 as suggested in the PLINK best practices. We used VEP 21 for functional annotation of the DNA variants. Common and rare variants analyses were conducted using PLINK/SEQ 22 , which allows indexing of the large datasets.
A burden test was used for rare protein truncating variants. In addition, the VT 23 and C-alpha 24 tests were chosen as an adaptive burden test and variancecomponent test, respectively, to complement each other and to boost the power of rare missense and protein truncating variation association detection 25 . See details in supplementary methods.
Statistical Methods. Gene-based association was performed using 3 distinct, but related, analytical frameworks. In the first analysis, a burden test was applied to all rare (MAF<1%) protein truncating variants (PTV) since the functional impact is presumed to be severe and most directly inferred. Then, to expand on all rare variants (missense and PTV), a second analysis using both the C-alpha and variable threshold (VT) tests was employed. A third analysis applied the burden test to examine "ultra-rare" (MAF<.0001; ExAC database 17 Supplementary figure captions could be found in supplementary information.
